NEW BRUNSWICK, N.J.—Johnson & Johnson (NYSE: JNJ) has reported 2024 second quarter sales growth of 4.3 percent to $22.4 billion, with operational growth of 6.6 percent. Reported second quarter sales in the U.S. totaled $12.6 billion, a 7.8 percent increase over the same period last year, the company announced. “Johnson & Johnson's second quarter performance reflects our relentless focus on advancing the next wave of medical innovation and resulted in strong sales and adjusted operational earnings per share growth,” said Joaquin Duato, chairman and chief executive officer.

“With a robust pipeline, upcoming regulatory milestones for Rybrevant and Tremfya, the integration of Shockwave, and continued expansion of newly launched products, including Acuvue Oasys Max 1-Day contact lenses and our Varipulse platform, we have a strong foundation for near and long-term growth,” Duato said.

MedTech worldwide operational sales grew 2.2 percent or 4.4 percent operationally, with acquisitions and divestitures positively impacting growth by 0.4 percent, the announcement stated. Operational sales growth was driven primarily by electrophysiology products and Abiomed in cardiovascular, previously referred to as interventional solutions, and wound closure products in general surgery. With the MedTech segment, vision sales increased 0.8 percent operationally, while contact lens sales saw 0.7 percent growth operationally. The recent launch of Acuvue Oasys Max 1-Day contact lenses is expected to boost sales for the reminder of the year, the company said.

“We expect MedTech growth to accelerate in the second half of the year,” Duato said on a second quarter earnings call. According to the company, MedTech growth is expected to come from recovery in contact lenses, evidenced by sequential monthly improvement within the second quarter, further expansion into high-growth markets, and continued growth of products and commercial execution across the portfolio.

Innovative Medicine worldwide operational sales, excluding the COVID-19 vaccine, grew 8.8 percent, according to the announcement. Growth was driven by Darzalex (daratumumab), Erleada (apalutamide), and others in oncology, Tremifya (guselkumab) and Stelara (ustekinumab) in immunology, and Spravato (esketamine) in neuroscience. Growth was partially offset by other neuroscience. Including the COVID-19 vaccine, innovative medicine worldwide operational sales grew 7.8 percent.

The company also increased its full-year 2024 operational sales guidance to reflect the acquisition of Shockwave Medical. Operational sales for full-year 2024 are now expected to be in the range of $89.2 billion to $89.6 billion compared with $88.7 billion to $89.1 billion in April 2024.